BRIACELL THERAPEUTICS ORD
CUSIP: 107930307
BRIACELL THERAPEUTICS ORD (BCTX) — institutional ownership and SEC 13F holdings data. Source: SEC EDGAR 13F filings.
About
BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, with a focus on breast cancer and other solid tumors. The firm is advancing tumor cell–based vaccine candidates and combination immunomodulatory approaches designed to trigger anti-tumor immune responses and improve the efficacy of checkpoint inhibitors in early-stage clinical trials. As a development-stage company, BriaCell’s progress depends on clinical data and collaborative partnerships to advance its pipeline and regulatory strategy.
Institutional Holders
Source: SEC EDGAR 13F-HR filings from institutional investment managers.
Try asking...